In Dr. Andtbacka's Current Status of Injectable Therapy presentation at the HemOnc Today Melanoma and Cutaneous Malignancies Symposium in March, around the 17:43 mark of the video, a bullet point referencing mid-2013 enrollment in the pivotal MM Phase 3 trial appears. As referenced in his presentation, Dr. Andtbacka obtained his information from Eric.
In last week's Provectus PR about PV-10 combination therapy, Eric's second quote appears to be a so-called strong reference to his current confidence about a potential start date.
Mid-2013 might mean June or July. Allowing 30 days, give or take, post-SPA receipt to commence the trial, the receipt of the SPA could be announced in May or June.
No comments:
Post a Comment